Pyxis Oncology Inc. reported a net loss of $22.0 million, or $0.35 per common share, for the quarter ended September 30, 2025, compared to a net loss of $21.2 million, or $0.35 per common share, for the same period in 2024. Excluding non-cash stock-based compensation expense, the net loss was $18.9 million for the quarter, versus $18.2 million for the prior year quarter. As of September 30, 2025, the company held $77.7 million in cash, cash equivalents, and short-term investments, with an expected cash runway into the second half of 2026. Business developments include ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma, with preliminary data expected in the fourth quarter of 2025. As of October 31, 2025, Pyxis Oncology had 62.3 million shares of common stock outstanding.